Connect with us


Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure
The post Touring Chiesi’s vision for…



Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – that is the Chiesi Group’s new Biotech Centre of Excellence, you would be forgiven for thinking this was just another laboratory and/or pharmaceutical manufacturing plant; because it quite simply isn’t.

Located on the outskirts of the historic Italian city – home to Verdi and myriad architectural gems – the press launch and tour of the €85 million Chiesi development was a quintessentially Italian affair, based out of Chiesi’s San Leonardo production site. Abuzz with cameras and tightly guarded by security, it was clear this was a seriously pivotal moment in the company’s history.

With three rows of press in attendance and an otherwise packed room of stakeholders and others with a vested interest, as the heat lamps burned down to warm what would have been a rather chilly industrial space in northern Italy, a hush settled, and the proceedings began.

In-house drug development of biologicals and rare disease targeting

In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting. The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. A B Corps company, Chiesi’s LEED Platinum certified Biotech Centre of Excellence will focus mainly on rare disease biologics – another shift in the family-business pharma’s image and action.

Having built a considerable reputation via its immunotherapies and respiratory products, Chiesi’s first rare disease drug is zampilimab, a novel monoclonal antibody for fibrotic lung diseases. Chiesi is also going to maximise access to Aptar Pharma’s digital platform. A respiratory platform similar to the diabetes one, the Digital Health Solution is yet another future-looking inclusion in the Chiesi plan.

An advance in biologics for Chiesi; an advancement for Italy as a whole

The founder himself, Alberto Chiesi opened the occasion. The purpose behind this new Biotech Centre of Excellence is not just as an advancement into the production of biological medicines for Chiesi; it is, rather, an advancement for Italy as a whole. Thanking those in attendance, notably the Deputy Minister, Valentino Valentini, and the President of the Emilia-Romagna region, Stefano Bonaccini, Alberto Chiesi noted how the quality of the company’s production and logistics made it possible to continue to bring its drugs to all patients who needed them during the challenges presented by the pandemic.

This new investment is, he said, an opportunity to strengthen the innovative capacity of the national biopharmaceutical sector and, by extension, the European one. Having a healthy and sustainable pharmaceutical sector is both a necessary requirement and a good one for society.

Alberto Chiesi also remarked that the industry is grappling with growing global competition, in which Europe is losing ground in R&D: 48% of new products globally are developed in the United States, compared with 25% in Europe. The situation was reversed only 25 years ago.

So, the Biotech Centre of Excellence will project the group towards the future of medicine and science. It is a strong message for Italy, and Parma in particular, being the location where the group was born and where its most important activities are based. Alberto Chiesi deemed Italian pharmaceutical industries the “reference leaders in Europe”. For Chiesi, it is important that the group lives up to its commitment, generating shared value, improving economic conditions, and the social aspects of the community in which it operates, and by extension, generating value for the country as a whole.

Going beyond the standards of care; improving drug safety and efficacy

Marcello Cattani, country lead and president and managing director, Italy & Malta, at Sanofi, as well as president of Farmindustria, spoke next, expressing that he couldn’t have been happier to be in attendance for the occasion.

Innovation, a right to health, and rare disease research – biotechnical drugs for such are what the future is being built on, he said. Already, the effects of the Biotech Centre of Excellence are being felt, not least in the employment opportunities it will create. The challenge facing the pharmaceutical industry today though, he said, is to go beyond the standards of care, and improve drugs to make them safer and more effective. At the same time, Cattani urged for new rules in governing pharmaceutical expenditure, as even today, expenditure ceilings are inadequate with respect to real function.

Next to speak was Antonio Magnelli, head of the global manufacturing division at Chiesi, who termed the Biotech Centre of Excellence a strengthening force for the future. Technology is to combine within its bounds, he said, so that it is possible to go from start to finish in drug development. An extremely ambitious project, then, and one with great responsibility to the region and to Italy. Then, head of pharmaceutical development GTD, R&D at Chiesi Pharmaceuticals, Francesca Usberti explained the full integration of processes that will be undertaken within the new lab, working with active ingredients, from enzymes and monoclonal antibodies and proteins up to the formulation of the finished product.

An historic moment for health, innovation, research, and employment

Afterwards, the Mayor of Parma, Michele Guerra, spoke. Terming the occasion an “historic moment”, he highlighted the key words reiterated by those who had gone before him: health, innovation, research, and employment. These, he said, are at the top of the agenda of any politician, also. Guerra reminded attendees of Alberto Chiesi’s notion of “interdependence”, a word that “presupposes solidarity”, and mused on the fact that although Chiesi is one of the most important pharmaceutical groups in the world, it is yet integrated into the neighbourhood of Parma.

Councillor Vincenzo Colla was next to share his thoughts, picking up on the Chiesi Group’s bond with Parma that Guerra had mentioned. B Corps-certified, it is the first multinational company in the world to receive such a commercial and industrial passport, he said. Furthermore, Chiesi has, as a rule, the attraction of talent: talent acquisition is what results in high-quality businesses, and the new Biotech Centre of Excellence will do precisely that. What the Chiesi Group is doing is making people safe and people’s safety comes first in any system, he said. But to make people safe requires a lot of research.

The President of the Emilia-Romagna Region, Stefano Bonaccini, took turn to speak next. Having led the region for almost six years, he noted how Parma has come on within that space of time and asserted that, in terms of merit and extraordinary enterprises, there is no other region in Europe quite like it. The Biotech Centre of Excellence aptly reinforces that.

Lastly, Vice Minister of Business and Made in Italy, Valentino Valentini spoke. Talking about the integrated supply chain that is always in play with France and Germany, he warned of continuous competition that could pose a gradual risk to Italy’s research basis in development research. And so, pharmaceutical spending is an investment, he said. Prevention is not the path followed for pathologies which are increasingly complex; reorganisation of expenditure, with clear purpose, must be made.

A site visit and photographs; interviews and touring through operations

Following the speeches, all major figures walked out to be captured in the midst of development, posing for snaps and answering press questions with what is still the shell of a building as a background to goings on. Then came an afternoon interlude of interviews within the offices of the company, after which the Chiesi Group held tours for its press visitors in both Italian and English.

Walking through both a floor of laboratories as if in a viewing gallery and donning a full outfit of protective wear in order to be guided through the extensive manufacturing side of operations – seeing first-hand just how important automation, as well as precision and hygiene, is in terms of safe and speedy delivery of medicine to patients – it can only be said that the excitement over this project is palpable, traversing both languages and regional and national borders. Certainly, it can be said that it seems as if the Chiesi Biotech Centre of Excellence shall bring into reality great things indeed.


The post Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence appeared first on .

Read More

Continue Reading


Who Owns The Most Satellites?

Who Owns The Most Satellites?

Nearly 7,000 satellites orbit the Earth, serving vital functions such as communication, navigation, and scientific…



Who Owns The Most Satellites?

Nearly 7,000 satellites orbit the Earth, serving vital functions such as communication, navigation, and scientific research.

In 2022 alone, more than 150 launches took place, sending new instruments into space, with many more expected over the next decade.

But who owns these objects? In this graphic, Visual Capitalist's Bruno Venditti and Miranda Smith utilize data from the Union of Concerned Scientists to highlight the leaders in satellite technology.

SpaceX’s Dominance in Space

SpaceX, led by Elon Musk, is unquestionably the industry leader, currently operating the largest fleet of satellites in orbit—about 50% of the global total.

The company has already completed 62 missions this year, surpassing any other company or nation, and operates thousands of internet-beaming Starlink spacecraft that provide global internet connectivity.

Starlink customers receive a small satellite dish that self-orients itself to align with Starlink’s low-Earth-orbit satellites.

Percentages may not add to 100 due to rounding.

In second place is a lesser-known company, British OneWeb Satellites. The company, headquartered in London, counts the UK government among its investors and provides high-speed internet services to governments, businesses, and communities.

Like many other satellite operators, OneWeb relies on SpaceX to launch its satellites.

Despite Starlink’s dominance in the industry, the company is set to face intense competition in the coming years. Amazon’s Project Kuiper plans to deploy 3,236 satellites by 2029 to compete with SpaceX’s network. The first of the fleet could launch as early as 2024.

The Rise of China’s Space Program

After the top private companies, governments also own a significant portion of satellites orbiting the Earth. The U.S. remains the leader in total satellites, when adding those owned by both companies and government agencies together.

American expenditures on space programs reached $62 billion in 2022, five times more than the second one, China.

China, however, has sped up its space program over the last 20 years and currently has the highest number of satellites in orbit belonging directly to government agencies. Most of these are used for Earth observation, communications, defense, and technology development.

Satellite Demand to Rise Over the Decade

Despite the internet being taken for granted in major metropolitan areas and developed countries, one out of every three people worldwide has never used the web.

Furthermore, the increasing demand for data and the emergence of new, more cost-effective satellite technologies are expected to present significant opportunities for private space companies.

In this context, satellite demand is projected to quadruple over the next decade.

Tyler Durden Thu, 09/28/2023 - 19:20

Read More

Continue Reading


NIH Doctor Flagged Wuhan Virus Lab Safety Problems As Early As 2017

NIH Doctor Flagged Wuhan Virus Lab Safety Problems As Early As 2017

Authored by Tom Ozimek via The Epoch Times,

A doctor working for the…



NIH Doctor Flagged Wuhan Virus Lab Safety Problems As Early As 2017

Authored by Tom Ozimek via The Epoch Times,

A doctor working for the U.S. government in 2017 visited the China-based virus research facility that may have leaked the pathogen that causes COVID-19, and sounded the alarm on safety issues at the lab earlier than previously reported, according to documents obtained by The Epoch Times.

Dr. Ping Chen, who worked for the National Institute of Allergy and Infectious Diseases (NIAID), visited the Wuhan Institute of Virology (WIV) in October 2017 and prepared a report for her superiors after her visit.

While a version of her report obtained by a Freedom of Information Act (FOIA) request was fully redacted, Sen. Ron Johnson (R-Wis.) and his team were granted an opportunity to carry out an in-camera review of the report that had some of the redactions removed.

“It is clear to me by talking to the technician that certainly there is a need for training support” at the Wuhan lab, Dr. Chen wrote in the report, parts of which were attached to a letter sent by Mr. Johnson to Department of Health and Human Services (HHS) Secretary Xavier Becerra on Sept. 21.

The letter, which was obtained by The Epoch Times, includes fragments of Dr. Chen's report and suggests that HHS and the U.S. National Institutes of Health (NIH) were aware of safety issues at the Wuhan facility as early as October 2017.

The P4 laboratory on the campus of the Wuhan Institute of Virology in Wuhan, Hubei Province, China, on May 13, 2020. (Hector Retamal/AFP via Getty Images)

Earlier reporting based on two State Department cables and correspondence records obtained by Judicial Watch indicate that NIH was made aware of safety problems at the Wuhan lab in 2018, the year after Dr. Chen's report.

“I think the institute would welcome any help and technical support by NIAID,” Dr. Chen wrote in her 2017 report.

Mr. Johnson wrote in his letter to Mr. Becerra that Dr. Chen's 2017 report partially served as the basis for a Jan. 19, 2018, State Department cable that raised safety concerns about the Wuhan virus lab.

Evidence suggests that SARS-CoV-2, the virus that causes COVID-19, leaked from the Wuhan facility before spreading across the world. According to the so-called lab leak theory, the deadly pathogen that caused the pandemic escaped the Chinese facility, which was conducting risky gain-of-function research on bat coronaviruses that was partially funded by U.S. taxpayer dollars.


Mr. Johnson demanded that HHS provide a version of Dr. Chen's 2017 report that contains fewer redactions in order to scrutinize its contents more closely and determine how closely it aligned with the cable.

“In the public FOIA document, HHS redacted Dr. Chen’s entire report claiming that it contains privacy and deliberative information,” Mr. Johnson wrote.

“It seems apparent that the only reason that HHS redacted this information was to hide the report’s contents from the American people. Perhaps HHS did not want the public to fully understand the fact that NIH and NIAID officials were aware of safety concerns at the WIV dating as far back as 2017,” he added.

Mr. Johnson also accused NIH and HHS of obstructing his probe.

"HHS and NIH continue to obstruct my oversight efforts," he wrote. "It is unacceptable that HHS and NIH had Dr. Chen's report in its possession and only provided a slightly less redacted version for my staff to review in camera."

He demanded that HHS provide unredacted copies of Dr. Chen's report and all documents and communications relating to the report and to the Wuhan lab.

Mr. Johnson also asked for Dr. Chen to sit before a congressional panel and testify.

He set an Oct. 5 deadline for HHS to comply with his request.

HHS officials didn't immediately respond to a request by The Epoch Times for comment.

Chinese virologist Shi Zhengli is seen inside the P4 laboratory in Wuhan, China, on Feb. 23, 2017. (Johannes Eisele/AFP via Getty Images)

'Preponderance of Evidence' for Lab Leak

In August 2021, a report by Republican lawmakers noted a "preponderance of evidence" that the virus that caused the COVID-19 pandemic leaked from the Wuhan lab.

Chinese officials have denied the lab leak claim, insisting that the virus made a natural jump from animals to humans.

Rep. Michael McCaul (R-Texas) said in testimony before the Coronavirus Select Subcommittee Republicans that evidence points to a lab leak as the likely origin of the virus, saying that "it's time to completely dismiss the wet market as the source of the outbreak" and "the preponderance of the evidence that it came from the lab is very convincing."

U.S. intelligence agencies later said in a report that a natural origin and a lab leak are both plausible hypotheses but that a lack of evidence makes a definitive conclusion either way impossible.

It's a sentiment echoed by Mr. McCaul in his testimony.

"Unfortunately, we may never know for certain because the Chinese Communist Party went to great lengths to cover up this outbreak," he said. "They detained the doctors in order to silence them. They disappeared journalists. They destroyed lab samples. They hid the fact there was clear evidence of human-to-human transmission. And they have refused to allow a real investigation into the origins."

Wuhan Lab Funding Controversy

The U.S. Agency for International Development awarded a total of $1.1 million to the WIV between October 2009 and May 2019, the agency wrote in a May 2021 letter (pdf) to Rep. Guy Reschenthaler (R-Pa.).

Mr. Reschenthaler alleged that the funding was used for a study that used gain-of-function research to create "a hybrid, man-made virus by inserting a spiked protein from a wild coronavirus into a mouse-adapted SARS-CoV backbone, which could infect human airways."

The agency said the funds were channeled through EcoHealth Alliance and were meant for the purpose of advancing research on critical viruses that could pose a threat to humans. It also denied claims that the money was used for gain-of-function research, which seeks to boost viral lethality for the purpose of studying it.

In June 2022, the House Appropriations Committee approved a ban on sending any further funding to the Wuhan Institute of Virology.

More recently, the NIH quietly removed the WIV from a list of foreign facilities that are eligible to receive U.S. taxpayer funds to conduct animal experiments.

Tyler Durden Thu, 09/28/2023 - 19:40

Read More

Continue Reading


Just 3 Nobel Prizes cover all of science – how research is done today poses a challenge for these prestigious awards

The Nobel Prize categories were set up more than a century ago. Since then, science has grown and evolved in unpredictable ways.




Has the Nobel Prize category 'chemistry' morphed into 'biochemistry'? picture alliance via Getty Images

I’ve been primarily an experimental chemist – the kind of person who goes into the laboratory and mixes and stirs chemicals – since the beginning of my career in 1965. Today, and for the past 15 years, I’m a full-time historian of chemistry.

Every October, when the announcements are made of that year’s Nobel laureates, I examine the results as a chemist. And all too often, I share the same response as many of my fellow chemists: “Who are they? And what did they do?”

One reason for that bewilderment – and disappointment – is that in many recent years, none of my “favorites” or those of my fellow chemists will travel to Stockholm. I am not suggesting that these Nobel laureates are undeserving – quite the opposite. Rather, I am questioning whether some of these awards belong within the discipline of chemistry.

Consider some recent Nobel Prizes. In 2020, Emmanuelle Charpentier and Jennifer A. Doudna received the Nobel Prize “for the development of a method for genome editing.” In 2018, Frances H. Arnold received the Nobel Prize “for the directed evolution of enzymes,” which she shared with George P. Smith and Sir Gregory P. Winter “for the phage display of peptides and antibodies.” In 2015, Tomas Lindahl, Paul Modrich and Aziz Sancar received the Nobel Prize “for mechanistic studies of DNA repair.”

All of them received Nobel Prizes in chemistry – not the Nobel Prize in physiology or medicine, even though these achievements seem very clearly situated within the disciplines of medicine and the life sciences. There are many other similar examples.

woman and man in formal dress at awards ceremony
2018 co-laureate Frances Arnold receives her Nobel Prize in chemistry from King Carl XVI Gustaf of Sweden. Henrik Montgomery/AFP via Getty Images

These recent mismatches are even clearer when you look further back in time. Consider the 1962 Nobel Prize awarded to Francis Crick, James Watson and Maurice Wilkins “for their discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material.” DNA, of course, is the most famous nucleic acid, and these three scientists were honored for deciphering how its atoms are bonded together and arranged in their three-dimensional double-helix shape.

While the “structure of DNA” most certainly is an achievement in chemistry, the Nobel Assembly at the Karolinska Institute in Stockholm awarded the Nobel Prize in physiology or medicine to Watson, Crick and Wilkins. Clearly, their Nobel achievements have had great consequences in the life sciences, genetics and medicine. Thus awarding them the Nobel Prize for physiology or medicine is quite appropriate.

metal model of structure of DNA molecule double helix
A model of a DNA molecule using some of Watson and Crick’s original metal plates. Science & Society Picture Library via Getty Images

But note the disconnect. The Nobel Prizes in chemistry in 2020, 2018 and 2015 are more life-science- and medicine-oriented than Watson, Crick and Wilkins’ for the structure of DNA. Yet the former were awarded in chemistry, while the latter was in physiology and medicine.

What is going on? What does this trend reveal about the Nobel Foundation and its award strategies in response to the growth of science?

A gradual evolution in the Nobel Prizes

Several years ago, chemist-historian-applied mathematician Guillermo Restrepo and I collaborated to study the relationship of scientific discipline to the Nobel Prize.

Each year, the Nobel Committee for chemistry studies the nominations and proposes the recipients of the Nobel Prize in chemistry to its parent organization, the Royal Swedish Academy of Sciences, which ultimately selects the Nobel laureates in chemistry (and physics).

We found a strong correlation between the disciplines of the members of the committee and the disciplines of the awardees themselves. Over the lifetime of the Nobel Prizes, there has been a continuous increase – from about 10% in the 1910s to 50% into the 2000s – in the percentage of committee members whose research is best identified within the life sciences.

Restrepo and I concluded: As go the expertise, interests and the disciplines of the committee members, so go the disciplines honored by the Nobel Prizes in chemistry. We also concluded that the academy has intentionally included more and more life scientists on their selection committee for chemistry.

Now some perceptive readers might ask, “Is not the discipline of biochemistry just a subdiscipline of chemistry?” The underlying question is, “How does one define the disciplines in science?”

Restrepo and I reasoned that what we term “intellectual territory” defines the boundaries of a discipline. Intellectual territory can be assessed by bibliographic analysis of the scientific literature. We examined the references, often called citations, that are found in scientific publications. These references are where authors of journal articles cite the related research that’s previously been published – often the research they have relied and built on. We chose to study two journals: a chemistry journal named Angewandte Chemie and a life science journal named, rather aptly, Biochemistry.

We found that the articles in Angewandte Chemie mostly cite articles published in other chemistry journals, and the articles in Biochemistry mostly cite articles in biochemistry and life sciences journals. We also found that the reverse is true: Scientific publications that cite Angewandte Chemie articles are mostly in chemistry journals, and publications that cite Biochemistry articles are mostly in biochemistry and life science journals. In other words, chemistry and the life sciences/biochemistry reside in vastly different intellectual territories that don’t tend to overlap much.

Not letting labels be limiting

But now, perhaps a shocker. Many scientists don’t really care how they are classified by others. Scientists care about science.

As I’ve heard Dudley Herschbach, recipient of the 1986 Nobel Prize in chemistry, respond to the oft-asked question of whether he’s an experimental chemist or a theoretical chemist: “The molecules don’t know, nor do they care, do they?”

But scientists, like all human beings, do care about recognition and awards. And so, chemists do mind that the Nobel Prize in chemistry has morphed into the Nobel Prize in chemistry and the life sciences.

black and white head shot of man in early 20th C attire
Jacobus Henricus van ‘t Hoff received the first Nobel Prize in chemistry for 'discovery of the laws of chemical dynamics and osmotic pressure in solutions.’ Universal History Archive/Universal Images Group via Getty Images

Since the Nobel Prizes were first awarded in 1901, the community of scientists and the number of scientific disciplines have grown tremendously. Even today, new disciplines are being created. New journals are appearing. Science is becoming more multidisciplinary and interdisciplinary. Even chemistry as a discipline has grown dramatically, pushing outward its own scholarly boundaries, and chemistry’s achievements continue to be astounding.

The Nobel Prize hasn’t evolved sufficiently with the times. And there just are not enough Nobel Prizes to go around to all the deserving.

I can imagine an additional Nobel Prize for the life sciences. The number of awardees could expand from the current three-per-prize maximum to whatever fits the accomplishment. Nobel Prizes could be awarded posthumously to make up for past serious omissions, an option that was used by the Nobel Foundation for several years and then discontinued.

In truth, the Nobel Foundation has evolved the prizes, but very deliberately and without the major transformations that I think will certainly be required in the future. It will, I believe, eventually break free, figuratively and literally, from the mire of Alfred Nobel’s will and more than a century of distinguished tradition.

When Nobel designed the prizes named after him in the late 1800s and early 1900s, he couldn’t have known that his gift would become a perpetual endowment and have such lasting – indeed, even increasing – significance. Nobel also could not have anticipated the growth of science, nor the fact that over time, some disciplines would fade in importance and new disciplines would evolve.

So far, the extremely competent and highly dedicated scholars at the Nobel Foundation and their partner organizations – and I acknowledge with real appreciation their selfless devotion to the cause – haven’t responded adequately to the growth of the sciences or to the inequities and even incompleteness of past award years. But I have confidence: In time, they will do so.

Jeffrey I. Seeman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading